TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF EUROPE Q-PCR REAGENTS MARKET 21
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
2.6 MULTIVARIATE MODELLING 31
2.7 DETECTION TYPE LIFELINE CURVE 31
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.9 DBMR MARKET POSITION GRID 33
2.10 MARKET APPLICATION COVERAGE GRID 34
2.11 VENDOR SHARE ANALYSIS 35
2.12 SECONDARY SOURCES 36
2.13 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 41
4.2 PORTERS FIVE FORCES 42
4.3 INDUSTRIAL INSIGHTS: 43
5 REGULATION 44
6 MARKET OVERVIEW 45
6.1 DRIVERS 47
6.1.1 INCREASE IN CHRONIC DISEASES AND COMMUNICABLE DISEASES 47
6.1.2 INCREASE IN GERIATRIC POPULATION 47
6.1.3 INCREASE IN EARLY DIAGNOSIS RATE 47
6.1.4 INCREASE IN ADVANCED TECHNOLOGY 48
6.2 RESTRAINTS 49
6.2.1 HIGH COST OF PRODUCT 49
6.2.2 ADVANCEMENT IN FIELD OF GENOMICS 49
6.3 OPPORTUNITIES 50
6.3.1 RISE IN GOVERNMENT FUNDING FOR HEALTHCARE 50
6.3.2 RISE IN HEALTHCARE EXPENDITURE 50
6.4 CHALLENGES 51
6.4.1 LACK OF SKILLED WORKFORCE 51
6.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 52
7 EUROPE Q-PCR REAGENTS MARKET, BY DETECTION TYPE 53
7.1 OVERVIEW 54
7.2 DYE-BASED REAGENTS 57
7.2.1 MASTER MIX 57
7.2.2 PRIMERS 57
7.2.3 DNA TEMPLATE 57
7.3 PROBE-BASED REAGENTS 58
7.3.1 MASTER MIX 58
7.3.2 PRIMERS 58
7.3.3 DNA TEMPLATE 58
8 EUROPE Q-PCR REAGENTS MARKET, BY ASSAY TYPE 59
8.1 OVERVIEW 60
8.2 QPCR SINGLEPLEX TEST/ASSAY 63
8.3 QPCR MULTIPLEX TEST/ASSAY 63
9 EUROPE Q-PCR REAGENTS MARKET, BY PLEXITY 64
9.1 OVERVIEW 65
9.2 DYE-BASED REAGENTS 68
9.2.1 SINGLEPLEX 68
9.2.2 MULTIPLEX 68
9.3 PROBE-BASED REAGENTS 68
9.3.1 SINGLEPLEX 69
9.3.2 MULTIPLEX 69
10 EUROPE Q-PCR REAGENTS MARKET, BY PACKAGING TYPE 70
10.1 OVERVIEW 71
10.2 KITS 74
10.3 MASTER MIXERS 74
11 EUROPE Q-PCR REAGENTS MARKET, BY TECHNOLOGY 75
11.1 OVERVIEW 76
11.2 GENE EXPRESSION 79
11.3 GENE TYPING 79
11.4 MIRNA ANALYSIS 79
11.5 PRE-AMPLIFICATION 80
11.6 VIRUS DETECTION 80
12 EUROPE Q-PCR REAGENTS MARKET, BY APPLICATION 81
12.1 OVERVIEW 82
12.2 RESEARCH 85
12.3 DIAGNOSTICS 85
12.4 FORENSIC 86
13 EUROPE Q-PCR REAGENTS MARKET, BY END USER 87
13.1 OVERVIEW 88
13.2 RESEARCH & ACADEMIC INSTITUTE 91
13.3 HOSPITAL AND DIAGNOSTIC CENTERS 91
13.4 CLINICAL RESEARCH ORGANIZATION 92
13.5 FORENSIC LABORATORIES 92
13.6 OTHERS 93
14 EUROPE Q-PCR REAGENTS MARKET, BY DISTRIBUTION CHANNEL 94
14.1 OVERVIEW 95
14.2 DIRECT TENDER 98
14.3 THIRD PARTY DISTRIBUTORS 98
14.4 OTHERS 99
15 EUROPE Q-PCR REAGENTS MARKET, BY COUNTRY 100
15.1 EUROPE 101
15.1.1 GERMANY 107
15.1.2 U.K. 110
15.1.3 FRANCE 113
15.1.4 ITALY 116
15.1.5 SPAIN 119
15.1.6 NETHERLANDS 122
15.1.7 SWITZERLAND 125
15.1.8 BELGIUM 128
15.1.9 POLAND 131
15.1.10 AUSTRIA 134
15.1.11 IRELAND 137
15.1.12 HUNGARY 140
15.1.13 NORWAY 143
15.1.14 RUSSIA 146
15.1.15 TURKEY 149
15.1.16 LITHUANIA 152
15.1.17 REST OF EUROPE 155
16 EUROPE Q-PCR REAGENTS MARKET: COMPANY LANDSCAPE 156
16.1 COMPANY SHARE ANALYSIS: EUROPE 156
17 SWOT ANALYSIS 157
18 COMPANY PROFILE 158
18.1 F. HOFFMANN-LA ROCHE LTD 158
18.1.1 COMPANY SNAPSHOT 158
18.1.2 REVENUE ANALYSIS 158
18.1.3 PRODUCT PORTFOLIO 159
18.1.4 RECENT DEVELOPMENT 159
18.2 MERCK KGAA 160
18.2.1 COMPANY SNAPSHOT 160
18.2.2 REVENUE ANALYSIS 160
18.2.3 PRODUCT PORTFOLIO 161
18.2.4 RECENT DEVELOPMENTS 161
18.2.4.1 PARTNERSHIP 161
18.2.4.2 NEW LABORATORY FACILITY 161
18.2.5 NEW DISTRIBUTION CENTER 161
18.3 THERMO FISHER SCIENTIFIC INC 162
18.3.1 COMPANY SNAPSHOT 162
18.3.2 REVENUE ANALYSIS 162
18.3.3 PRODUCT PORTFOLIO 163
18.3.4 RECENT DEVELOPMENTS 163
18.3.4.1 ACQUISITION 163
18.3.4.2 PRODUCT LAUNCH 163
18.4 AGILENT TECHNOLOGIES, INC 164
18.4.1 COMPANY SNAPSHOT 164
18.4.2 REVENUE ANALYSIS 164
18.4.3 PRODUCT PORTFOLIO 165
18.4.4 RECENT DEVELOPMENTS 165
18.4.4.1 DISTRIBUTION AGREEMENT 165
18.4.4.2 PRODUCT LAUNCH 165
18.5 SEEGENE INC. 166
18.5.1 COMPANY SNAPSHOT 166
18.5.2 PRODUCT PORTFOLIO 166
18.5.3 RECENT DEVELOPMENT 166
18.5.3.1 PRODUCT SUPPLY 166
18.6 BIONEER CORPORATION 167
18.6.1 COMPANY SNAPSHOT 167
18.6.2 PRODUCT PORTFOLIO 167
18.6.3 RECENT DEVELOPMENT 167
18.6.3.1 AGREEMENT 167
18.7 BIO-RAD LABORATORIES, INC. 168
18.7.1 COMPANY SNAPSHOT 168
18.7.2 REVENUE ANALYSIS 168
18.7.3 PRODUCT PORTFOLIO 169
18.7.4 RECENT DEVELOPMENTS 169
18.7.4.1 PARTNERSHIP 169
18.7.5 AWARD 169
18.8 BIOTIUM 170
18.8.1 COMPANY SNAPSHOT 170
18.8.2 PRODUCT PORTFOLIO 170
18.8.3 RECENT DEVELOPMENTS 171
18.9 ENZO BIOCHEM INC 172
18.9.1 COMPANY SNAPSHOT 172
18.9.2 REVENUE ANALYSIS 172
18.9.3 PRODUCT PORTFOLIO 173
18.9.4 RECENT DEVELOPMENT 173
18.10 GENEDIREX, INC 174
18.10.1 COMPANY SNAPSHOT 174
18.10.2 PRODUCT PORTFOLIO 174
18.10.3 RECENT DEVELOPMENT 174
18.11 KANEKA EUROGENTEC S.A 175
18.11.1 COMPANY SNAPSHOT 175
18.11.2 REVENUE ANALYSIS 175
18.11.3 PRODUCT PORTFOLIO 176
18.11.4 RECENT DEVELOPMENT 176
18.11.4.1 PRODUCT LAUNCH 176
18.12 MIRXES PTE LTD 177
18.12.1 COMPANY SNAPSHOT 177
18.12.2 PRODUCT PORTFOLIO 177
18.12.3 RECENT DEVELOPMENT 177
18.13 NORGEN BIOTEK CORP 178
18.13.1 COMPANY SNAPSHOT 178
18.13.2 PRODUCT PORTFOLIO 178
18.13.3 RECENT DEVELOPMENT 178
18.14 NEW ENGLAND BIOLABS 179
18.14.1 COMPANY SNAPSHOT 179
18.14.2 PRODUCT PORTFOLIO 179
18.14.3 RECENT DEVELOPMENTS 180
18.14.3.1 AQUISITION 180
18.14.4 PRODUCT LAUNCH 180
18.14.5 SUBSIDIARY 180
18.15 PCR BIOSYSTEMS 181
18.15.1 COMPANY SNAPSHOT 181
18.15.2 PRODUCT PORTFOLIO 181
18.15.3 RECENT DEVELOPMENT 181
18.16 PROMEGA CORPORATION 182
18.16.1 COMPANY SNAPSHOT 182
18.16.2 PRODUCT PORTFOLIO 182
18.16.3 RECENT DEVELOPMENT 182
18.16.3.1 R&D FACILITY 182
18.17 QIAGEN 183
18.17.1 COMPANY SNAPSHOT 183
18.17.2 REVENUE ANALYSIS 183
18.17.3 PRODUCT PORTFOLIO 184
18.17.4 RECENT DEVELOPMENTS 184
18.17.4.1 NEW FACILITY 184
18.17.4.2 ACQUISITION 184
18.18 QUANTABIO 185
18.18.1 COMPANY SNAPSHOT 185
18.18.2 PRODUCT PORTFOLIO 185
18.18.3 RECENT DEVELOPMENTS 185
18.18.3.1 CONFERENCE 185
18.18.3.2 PRODUCT LAUNCH 186
18.19 SINO BIOLOGICAL INC. 187
18.19.1 COMPANY SNAPSHOT 187
18.19.2 PRODUCT PORTFOLIO 187
18.19.3 RECENT DEVELOPMENT 187
18.19.3.1 NEW FACILITY 187
18.20 SOLIS BIODYNE 188
18.20.1 COMPANY SNAPSHOT 188
18.20.2 PRODUCT PORTFOLIO 188
18.20.3 RECENT DEVELOPMENT 188
18.20.3.1 R&D FACILITY 188
18.21 TAKARA HOLDINGS INC 189
18.21.1 COMPANY SNAPSHOT 189
18.21.2 REVENUE ANALYSIS 189
18.21.3 PRODUCT PORTFOLIO 190
18.21.4 RECENT DEVELOPMENTS 190
18.21.4.1 MANUFACTURING UNIT 190
18.21.5 ISO CERTIFICATION 190
18.22 YOUSEQ LTD 191
18.22.1 COMPANY SNAPSHOT 191
18.22.2 PRODUCT PORTFOLIO 191
18.22.3 RECENT DEVELOPMENT 191
18.22.3.1 ISO CERTIFICATION 191
19 QUESTIONNAIRE 192
20 RELATED REPORTS 195

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.